Latest news with #hormoneTherapy
Yahoo
09-07-2025
- Health
- Yahoo
Mary Claire Haver
Credit - Eric McCandless—Disney/Getty Images Fifteen percent of women glide through menopause. Dr. Mary Claire Haver was not among them, suffering debilitating hot flashes and sleepless nights. She also noticed that, even though the condition will affect about half the population, information on how to manage symptoms was hard to find. (Last year, a British study showed that only 9% of women felt informed enough to handle menopause.) So, the telegenic Dr. Haver, a board-certified ob-gyn based in Texas, stepped into the breach. In 2021, she opened her own clinic in Galveston; in 2023, she published a book on menopause diets; and in 2024, she followed up with The New Menopause, a comprehensive guide for women. Both sold briskly, but it's on social media where the 56-year-old's advice really lands—particularly on Instagram, where she speaks to her nearly 3 million followers, offering advice and talking through the latest research. Her guidance is considered aggressive by some menopause experts—she's an advocate for hormone therapy—and her promotion of her own supplements and diet plans has raised eyebrows. But her intelligence and candor have made her a staple for the 45-and-over set. As she told TIME last year, 'This is a time when we should be living our best lives.' Data and insights powered by #paid Contact us at letters@
The Independent
09-07-2025
- Health
- The Independent
Why women are at higher risk of having Alzheimer's than men
Wo men are twice as likely as men to develop Alzheimer's disease, accounting for almost two-thirds of American sufferers. Scientists are investigating two primary biological differences: chromosomal variations, particularly genes on the X chromosome. The natural decline of reproductive hormones during menopause is also considered a significant factor contributing to women 's increased risk. Research suggests that women who received hormone replacement therapy after age 70 exhibited higher levels of the Alzheimer's hallmark protein 'tau' and greater cognitive decline. Further studies are required to fully comprehend the complex associations between menopause, hormonal changes, and the long-term risk of developing Alzheimer's.
New York Times
03-06-2025
- Health
- New York Times
Judge Blocks Trump Effort to End Treatment for Transgender Inmates
The U.S. Bureau of Prisons must provide transgender inmates with hormone therapy and social accommodations such as gender-appropriate clothing while a lawsuit over the issue proceeds, a federal judge ruled on Tuesday. The ruling, by Judge Royce C. Lamberth of the U.S. District Court for the District of Columbia, also certified a class-action lawsuit filed on behalf of more than 1,000 inmates who have been diagnosed with gender dysphoria. The lawsuit claims the Trump administration's policy denying gender-related treatment to prisoners violates their Eighth Amendment right to medical care and the Administrative Procedure Act, which prohibits 'arbitrary and capricious' actions by federal agencies. In his order, Judge Lamberth said it was not necessary to address the constitutional issue at this stage of the case because the plaintiffs were likely to prevail on Administrative Procedure Act grounds. Under the act, he wrote, the Bureau of Prisons 'may not arbitrarily deprive inmates of medications or other lifestyle accommodations that its own medical staff have deemed to be medically appropriate without considering the implications of that decision.' Judge Lamberth was appointed by President Ronald Reagan. The ruling temporarily blocks a policy that stemmed from an executive order, issued by President Trump the day he took office, that no federal funds be spent for medical treatments 'for the purpose of conforming an inmate's appearance to that of the opposite sex.' That order, part of a broader push to eliminate protections for transgender people in the United States, suggested that recognizing the legitimacy of gender identities that do not match a person's biological sex 'has a corrosive impact' on the 'entire American system.' One plaintiff in the suit, Alishea Kingdom, a transgender woman who had been receiving hormone therapy since 2016, was denied hormone injections under the new policy, though she later began receiving them again, according to court documents. Two other plaintiffs, both transgender men, were told that their hormone therapies would not be renewed. Each was denied access to undergarments or hygiene products that corresponded with their gender identity. About 600 inmates with gender dysphoria are receiving hormone treatments, according to the Bureau of Prisons. The judge's order does not require the bureau to provide gender-related surgeries. The number of inmates requesting such operations is minuscule, and only two such surgeries are known to have been performed on inmates. Gender dysphoria can 'produce severe side effects ranging from depression and anxiety to suicidal ideation and self-harm if inadequately treated,' the judge wrote, adding that the Bureau of Prisons 'does not dispute this medical reality.' He wrote that it was not necessary to take into account debates over the efficacy of hormone therapies in his decision to issue a preliminary injunction against the policy. 'To conclude that the defendants have failed to meet the procedural strictures of the APA,' Judge Lamberth wrote, referring to the Administrative Procedure Act, 'is not to take any position on the underlying merits of the BOP's substantive policy decisions or the goals motivating the Executive Order.'
Daily Mail
29-05-2025
- Health
- Daily Mail
AI test could help to cut the risk of dying from prostate cancer by half, study suggests
A revolutionary AI test can help slash the risk of dying from prostate cancer by up to half, a breakthrough study suggests. From examining images of tumours it was able to identify patients who could benefit from a 'game-changer' drug by picking out features invisible to the human eye. Around one in four men with 'high-risk' prostate cancer were found to have a particular biomarker that made them more receptive to the treatment. Among those with the biomarker, taking the drug abiraterone alongside standard hormone therapy cut the risk of death after five years from 17 per cent to 9 per cent – a reduction of 47 per cent. Men without the biomarker saw their risk of death drop from 7 per cent to 4 per cent – which is not thought to be statistically or clinically significant. Abiraterone, which costs just £77 for a month's supply since the patent expired, works by inhibiting the production of testosterone in all tissues throughout the body, including in the tumour. Researchers say NHS England should now make the drug available to the 2,100 men a year who could benefit, while sparing others a treatment that comes with additional side-effects. It is approved for use on the NHS in England for patients with advanced prostate cancer that has come back and spread to other parts of the body, but not for the 8,400 men a year with newly diagnosed high-risk prostate cancer that has not spread. Experts say because fewer men than previously thought will need the drug, NHS England should review the decision not to fund the treatment for those who could benefit earlier. It has been more widely available to men in Scotland and Wales for two years. Scientists from the Institute of Cancer Research (ICR), in London, and University College London examined data from more than 1,000 men whose tumours were at high risk of spreading. The findings, based on a test developed by Artera Inc, will be presented at the American Society of Clinical Oncology Annual Meeting in Chicago. The Mail has campaigned for years to improve the diagnosis and treatment of prostate cancer in a bid to prevent needless deaths. Professor Nick James, who co-led the research at the ICR, said: 'I truly hope this new research – showing precisely who needs the drug to live well for longer – will lead to NHS England reviewing their decision to fund abiraterone for high-risk prostate cancer that has not spread.' An NHS spokesman said: 'Abiraterone continues to be routinely funded by the NHS in England for several forms of advanced prostate cancer in line with clinical guidance, and we are keeping this position under close review.' Meanwhile, lung cancer patients will be offered a new blood test to speed up access to targeted treatments and avoid unnecessary biopsies. The 'liquid biopsy' looks for tiny fragments of tumour DNA and detects mutations. About 15,000 patients a year will benefit, NHS England says.
CBC
28-05-2025
- Health
- CBC
Canadian Medical Association takes Alberta to court over Bill 26
A law that prohibits doctors from using puberty blockers and hormone therapy on youth under the age of 16 is facing another legal challenge.
